Long-term Follow-up for Safety Evaluation of Subjects Who Participated in the Phase 1 Clinical Trial of CS20AT04(CS20AT04-LN101) in Lupus Nephritis
Latest Information Update: 13 Jan 2025
At a glance
- Drugs CS20AT04 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors CORESTEM; Corestemchemon
Most Recent Events
- 06 Nov 2024 Status changed from active, no longer recruiting to completed.
- 26 Feb 2024 Planned End Date changed from 24 Jan 2024 to 24 May 2024.
- 24 Aug 2020 Status changed from recruiting to active, no longer recruiting.